Serum anti-glycan antibodies predict complicated crohn's disease behavior: A cohort study

Inflammatory Bowel Diseases

Volumn 16, Issue 8, 2010, Pages 1367-1375

  Rieder, Florian ^a   Schleder, Stephan ^a   Wolf, Alexandra ^a   Dirmeier, Andrea ^a   Strauch, Ulrike ^a   Obermeier, Florian ^a   Lopez, Rocio ^a   Spector, Larissa ^b   Fire, Ella ^c   Yarden, Jennifer ^c   Rogler, Gerhard ^d   Dotan, Nir ^c   Klebl, Frank ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Glycominds Ltd   (Israel)

^d Clinic for Gastroenterology and Hepatology   (Switzerland)

Author keywords

Anti C; Anti L; Antibody; Crohn's; Prediction

Indexed keywords

CHITIN; GLYCAN; GLYCAN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LAMINARAN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

ADULT; ANTIBODIES; CHITIN; COHORT STUDIES; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 77955753843     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21179     Document Type: Article

References (24)

1. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782 (Pubitemid 33096034)
2. Farmer RG, Whelan G, Fazio VW.Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985;88:1818-1825
3. Andres PG, Friedman LS.Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:255-281 (Pubitemid 29306479)
4. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241 (Pubitemid 40139240)
5. Devlin SM, Dubinsky MC.Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis. 2008;14:125-128 (Pubitemid 351196877)
6. Targan SR.The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis. 1999;5:61-63
7. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306 (Pubitemid 39069929)
8. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689-699 (Pubitemid 34977074)
9. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403 (Pubitemid 47517833)
10. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131:366-378 (Pubitemid 44142445)
11. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-681
12. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2009 [Epub ahead of print].
13. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;10:1105-1111
14. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am Gastroenterol. 2006;101:360-367
15. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006;101:645-652 (Pubitemid 43340944)
16. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55(suppl 1):i1-15
17. Mandrekar JN, J. MS, S. CS. Cutpoint determination methods in survival analysis using SAS. Proceedings of the 28th SAS Users Group International Conference (SUGI). 2003; Paper 261.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36
19. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496
20. Tang LY, Rawsthorne P, Bernstein CN.Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol. 2006;4:1130-1134 (Pubitemid 44311656)
21. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438 (Pubitemid 350181602)
22. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122
23. Eser A, Papay P, Miehsler W, et al. Impact of intestinal resection on and prognostic value of anti-Saccaromyces cerevisiae serology in patients with Crohn's disease during long-term follow-up. Gastroenterology. 2009;136:A-188
24. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol. 2003;98:2226-2231 (Pubitemid 37305363)